NOT
FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN,
INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A
VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH
JURISDICTION.
15 October
2024
Oxford Nanopore Technologies plc ("Oxford Nanopore" or "the
Company")
Issue of Equity and Total Voting Rights
The Company today announces in
respect of the period from 1 October to 14 October 2024, the issue
of 12,566,031 ordinary shares of £0.0001 each,
following:
· the issue
of 12,500,789 ordinary shares to satisfy the vesting of awards
under the Oxford Nanopore Technologies Limited Long-Term Incentive
Plan 2021; and
· the
exercise of options granted under the Company's share option plans
and issuance of shares under certain of the Company's remuneration
schemes and such ordinary shares were admitted to the Official List
of the Financial Conduct Authority ("FCA") and to
trading on the London Stock Exchange's main market for listed
securities under the Company's block listing facility. Following
this issue, the Company has the ability to admit a further 65,242
ordinary shares under its block listing facility.
In accordance with the FCA's
Disclosure Guidance and Transparency Rule 5.6.1, the Company
announces that as at 14 October 2024, the Company's issued share
capital consisted of 954,021,220 ordinary shares, one class A
limited anti-takeover ("LAT") share of
£1.00, one class B LAT share of £1.00 and one class C LAT share of
£1.00 and the Company will not hold any shares in treasury. Only
the ordinary shares are voting shares and each such ordinary share
carries one vote per ordinary share. As
outlined in the Company's IPO Prospectus, the LAT shares could
carry their rights for up to three years from the date of
admission. Therefore, on 5 October 2024, the LAT shares ceased to
carry any of their rights. Accordingly, the
total number of voting rights in the Company as at 14 October 2024
is 954,021,220. This figure may be used by shareholders as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, the Company under the FCA's Disclosure Guidance and
Transparency Rules.
For further information, please
contact:
Oxford Nanopore Technologies plc
Investors:
ir@nanoporetech.com
Media:
media@nanoporetech.com
Teneo (communications adviser
to the
Company)
Tom Murray, Olivia Peters
+44 (0) 20 7353 4200
OxfordNanoporeTechnologies@teneo.com
About Oxford Nanopore Technologies plc:
Oxford Nanopore Technologies' goal is to bring the widest
benefits to society through enabling the analysis of anything, by
anyone, anywhere. The company has developed a new generation of
nanopore-based sensing technology for real-time, high-performance,
accessible and scalable analysis of DNA and RNA. The technology is
used in more than 120 countries to understand the biology of humans
and diseases such as cancer, plants, animals, bacteria, viruses and
whole environments. Oxford Nanopore Technologies products are
intended for molecular biology applications and are not intended
for diagnostic purposes.
www.nanoporetech.com
Forward-looking statements
This announcement contains certain
forward-looking statements. For example, statements regarding
expected revenue growth and profit margins are forward-looking
statements. Phrases such as "aim", "plan", "expect", "intend",
"anticipate", "believe", "estimate", "target", and similar
expressions of a future or forward-looking nature should also be
considered forward-looking statements. Forward-looking statements
address our expected future business and financial performance and
financial condition, and by definition address matters that are, to
different degrees, uncertain. Our results could be affected by
macroeconomic conditions, the COVID-19 pandemic, delays in our
receipt of components or our delivery of products to our customers,
suspensions of large projects and/or acceleration of large products
or accelerated adoption of pathogen surveillance. These or other
uncertainties may cause our actual future results to be materially
different than those expressed in our forward-looking
statements.